Overview
Dr Judd Moul joined the Duke faculty in mid 2004 after a career in the US Army Medical Corps mainly at Walter Reed Army Medical Center. He is a retired colonel and a noted researcher and clinician in the area of prostate cancer and is a urologic oncologist. He served as the division chief of Duke Division of Urology from 2004 to 2011 and was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first named endowed chair for urology. He was awarded the Gold Cystoscope Award from the American Urologic Association as well as Castle Connelly Physician of the year for Clinical Medicine in 2009. He has performed more than 1300 radical prostatectomies since joining the Duke faculty and is committed to outcomes research on this series and in other areas of prostate cancer. He served as the Editor for Prostate Cancer and Prostatic Dissease, a Nature Medicine journal, for more than a decade and is a popular speaker and lecturer having been visiting professor and keynote speaker throughout the US and the World. He is very committed to training residents and mentoring students and trainees.
Office Hours
Clinic days: Tuesday and Thursday from 8am to 530pm
OR Days: 1st,3rd and 5th Mondays and selected Wednesdays and Fridays
Telehealth Clinics 2nd and 4h Mondays as selected other days
OR Days: 1st,3rd and 5th Mondays and selected Wednesdays and Fridays
Telehealth Clinics 2nd and 4h Mondays as selected other days
Current Appointments & Affiliations
James H. Semans, M.D. Distinguished Professor of Urologic Surgery, in the School of Medicine
·
2009 - Present
Urology,
Clinical Science Departments
Professor of Urology
·
2005 - Present
Urology,
Clinical Science Departments
Professor in Anesthesiology
·
2012 - Present
Anesthesiology,
Clinical Science Departments
Member of the Duke Cancer Institute
·
2004 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Real-world analyses of major adverse cardiovascular events and mortality risk after androgen deprivation therapy initiation in black vs. white prostate cancer patients.
Journal Article Prostate Cancer Prostatic Dis · April 18, 2025 BACKGROUND: Prostate cancer(PCa) patients treated with androgen deprivation therapy(ADT) may experience major adverse cardiovascular events(MACE) [1]. Racial disparities in PCa incidence and outcomes have been noted. In contrast to older studies, three rec ... Full text Link to item CiteGenetic ancestry concordant RNA splicing in prostate cancer involves oncogenic genes and associates with recurrence.
Journal Article NPJ Precis Oncol · January 29, 2025 Black men suffer disproportionately from prostate cancer (PCa) compared to men of other races and ethnicities. Comparing the molecular landscape of PCa among Black and White patients has the potential to identify targets for development of new precision me ... Full text Link to item CiteThe Role of Sleep Apnea in Postoperative Neurocognitive Disorders Among Older Noncardiac Surgery Patients: A Prospective Cohort Study.
Journal Article Anesth Analg · January 1, 2025 BACKGROUND: Obstructive sleep apnea is associated with increased dementia risk, yet its role in postoperative neurocognitive disorders is unclear. Here, we studied whether the severity of untreated obstructive sleep apnea is associated with the severity of ... Full text Link to item CiteRecent Grants
A Prospective Trial - Evaluation of ExoDx Prostate in Men with Prostate Cancer in an Active Surveillance Regimen
Clinical TrialPrincipal Investigator · Awarded by Exosome Diagnostics, Inc. · 2022 - 2026Phase III Randomized Efficacy and Safety Study
Clinical TrialPrincipal Investigator · Awarded by Medivation, Inc. · 2016 - 2026NWU22-12-01 A PHASE 2 PLACEBO-CONTROLLED TRIAL OF UROLITHIN A SUPPLEMENTATION IN MEN WITH PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY
ResearchCo Investigator · Awarded by Northwestern University · 2024 - 2025View All Grants
Education, Training & Certifications
Thomas Jefferson University ·
1982
M.D.
Pennsylvania State University ·
1979
B.S.